Veracyte Posts Strong 2025 Growth on Double-Digit Revenue Gains
Event summary
- Veracyte reported a 19% year-over-year revenue increase to $140.6 million in Q4 2025, with full-year revenue up 16% to $517.1 million.
- Decipher and Afirma tests drove growth, with Decipher revenue up 27% and Afirma revenue up 16% in Q4 2025.
- The company generated $52.6 million in cash from operations in Q4 2025 and ended the year with $412.9 million in cash reserves.
- Veracyte plans to launch Prosigna as an LDT and TrueMRD in 2026, expanding its diagnostic offerings.
The big picture
Veracyte's strong financial performance in 2025 underscores the growing demand for advanced cancer diagnostics. The company's focus on expanding its diagnostic portfolio through new product launches positions it to capture a larger share of the oncology testing market. However, sustaining growth will require continued investment in clinical evidence and operational efficiency.
What we're watching
- Product Expansion
- The launch of Prosigna as an LDT and TrueMRD in 2026 will test Veracyte's ability to integrate new diagnostics into its existing portfolio.
- Market Penetration
- Whether Veracyte can sustain double-digit growth across its core testing business amid increasing competition in cancer diagnostics.
- Operational Efficiency
- The pace at which Veracyte can maintain high profitability margins while scaling operations globally.
Our editorial coverage:
Related topics